Related Experiment Video

Updated: May 28, 2025

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.2K

'Where is my gap': mechanisms underpinning PARP inhibitor sensitivity in cancer

Lauryn Buckley-Benbow1, Alessandro Agnarelli1, Roberto Bellelli1

  • 1Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, Barbican, London EC1M 6BQ, U.K.

Biochemical Society Transactions
|February 10, 2025
PubMed

Insights

Poly-ADP ribose polymerase (PARP) inhibitors offer new breast cancer treatments for BRCA-mutant cancers. Replicative gaps are key to understanding sensitivity and overcoming resistance to these vital therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly-ADP ribose polymerase (PARP) inhibitors (PARPi) have revolutionized treatment for BRCA1/BRCA2-mutant cancers.
  • Primary and secondary resistance to PARPi presents a significant clinical challenge, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review current knowledge on PARPi sensitivity and resistance mechanisms.
  • To highlight the emerging role of replicative gaps in mediating PARPi response.

Main Methods:

  • Literature review of studies on PARP inhibitors, DNA damage response, and cancer genetics.
  • Analysis of evidence linking replicative gaps to PARPi sensitivity in various cancer types.

Main Results:

  • A unifying model for PARPi sensitivity is still under development.
  • Increasing evidence suggests replicative gaps are crucial for sensitizing both BRCA-mutant and wild-type cancer cells to PARPi.

Conclusions:

  • Replicative gaps represent a promising target for enhancing PARPi efficacy.
  • Further research is needed to overcome PARPi resistance and optimize clinical utilization.
Keywords:
BRCAPARPiPOLE3-POLE4replicative gaps

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

3.9K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K